Merus (MRUS)
(Delayed Data from NSDQ)
$55.23 USD
+1.04 (1.92%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $55.24 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Merus N.V. [MRUS]
Reports for Purchase
Showing records 21 - 40 ( 176 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Treatment Paradigm Pulse-A Prospective Look at EGFR Inhibitors in NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Zenocutuzumab Set to Explore Combinations and Cancers Outside NRG1+; Reit. Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2Q22: Data from Additional Assets, BLA for Lead Product in the Horizon
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Targeted Bispecific for NRG Cancers. Data Supports Filing With the FDA
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Positive Zeno Update During ASCO ?22 Shapes a Compelling Case for Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Zeno Looks to Shine During ASCO 2022 As Other Biclonics Push Forward; Reit. Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
AACR 2022 Abstract Titles Released (Part II): CGEN, GNTA, MRUS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Bullish on Zeno Update (1H22) Furthering the Chances for Agnostic Label; Reit. Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T